Form 483 & Warning Letter Responses
We help you draft clear, defensible, and technically sound responses to FDA observations — with realistic timelines and CAPA commitments your team can actually deliver on.
FDA Compliance
We help sterile and non-sterile drug manufacturers respond to FDA findings, prepare for inspections, and build regulatory submissions that hold up to scrutiny — without losing sight of the business objective.
Service
detail
A Form 483 observation or Warning Letter is rarely just a paperwork problem — it's a signal that your quality system needs a closer look. We help you respond quickly and credibly, then build the underlying systems so the same issue doesn't resurface at your next inspection.
Back to all services
What we help with
Support that helps put the right response, review, and quality system around critical regulatory priorities.
Service breakdown
We help you draft clear, defensible, and technically sound responses to FDA observations — with realistic timelines and CAPA commitments your team can actually deliver on.
Beyond the initial response, we help you design and execute a remediation plan that addresses root cause, not just the symptom the FDA flagged.
Before the FDA arrives, we run a mock audit that mirrors real inspection conditions — surfacing gaps in documentation, procedures, and facility readiness while there's still time to fix them.
We assess suppliers, CMOs, and contract testing labs against CGMP expectations, giving you clear visibility into third-party risk before it becomes your risk.
We review submissions for regulatory accuracy and completeness, helping reduce the risk of delays, deficiency letters, or follow-up information requests.
Who this is for
Whether you manufacture sterile injectables, ophthalmic and otic products, oral dosage forms, or transdermal and transmucosal products, our FDA compliance support adapts to your facility, product type, and regulatory history — branded, generic, OTC, or compounded.
Talk to an expertHow we work
The same four-step engagement path used across Steripharm services, contextualized to FDA compliance.
We review the FDA finding or inspection concern and clarify exactly what's being asked of you.
We prioritize the systems, records, and risks most relevant to the observation.
We support the response, remediation, or audit itself — hands-on, not just advisory.
We help the fix become a lasting part of your quality system, not a one-time patch.
FAQ
What manufacturers ask most about responses, audits, and remediation.
Ask a different questionFDA response timelines are tight, so we prioritize an initial review and response plan as soon as you engage us — typically within days, not weeks.
Yes. Mock pre-approval audits are one of our core services, designed to surface gaps before the FDA does.
Yes. Vendor audits and due diligence are part of our FDA compliance service, since third-party risk becomes your risk during an inspection.
Both. We support everything from a single observation response to a full remediation program.
Related services
From disposition and batch record review to investigations, CAPA, technology transfer, method validation, and environmental monitoring.
Explore Quality Assurance & ControlSee how FDA compliance and quality assurance work together across the full Steripharm service offering.
View all servicesStart with clarity
Talk with Steripharm Solutions about your FDA compliance objective.

